Effect of dual residual risk of cholesterol and inflammation on all … – Cardiovascular Diabetology

Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme AK, Buxton AE, Carson AP, Commodore-Mensah Y, et al. Heart Disease and Stroke Statistics-2022 update: a Report from the American Heart Association. Circulation. 2022;145(8):e153e639.

Article PubMed Google Scholar

writing committee of the report on. Cardiovascular h, diseases in c: report on Cardiovascular Health and Diseases in China 2021: an updated Summary. Biomed Environ Sci. 2022;35(7):573603.

Google Scholar

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):11188.

Article PubMed Google Scholar

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):111931.

Article CAS PubMed Google Scholar

Gencer B, Mach F, Murphy SA, De Ferrari GM, Huber K, Lewis BS, Ferreira J, Kurtz CE, Wang H, Honarpour N, et al. Efficacy of Evolocumab on Cardiovascular Outcomes in patients with recent myocardial infarction: a prespecified secondary analysis from the FOURIER Trial. JAMA Cardiol. 2020;5(8):9527.

Article PubMed Google Scholar

Bohula EA, Giugliano RP, Leiter LA, Verma S, Park JG, Sever PS, Lira Pineda A, Honarpour N, Wang H, Murphy SA, et al. Inflammatory and cholesterol risk in the FOURIER Trial. Circulation. 2018;138(2):13140.

Article CAS PubMed Google Scholar

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al. Evolocumab and Clinical Outcomes in patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):171322.

Article CAS PubMed Google Scholar

Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390(10106):196271.

Article CAS PubMed Google Scholar

Ridker PM, MacFadyen JG, Glynn RJ, Bradwin G, Hasan AA, Rifai N. Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular inflammation reduction trial. Eur Heart J. 2020;41(31):295261.

Article CAS PubMed PubMed Central Google Scholar

Peikert A, Kaier K, Merz J, Manhart L, Schafer I, Hilgendorf I, Hehn P, Wolf D, Willecke F, Sheng X, et al. Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort. Clin Res Cardiol. 2020;109(3):31523.

Article CAS PubMed Google Scholar

Guedeney P, Claessen BE, Kalkman DN, Aquino M, Sorrentino S, Giustino G, Farhan S, Vogel B, Sartori S, Montalescot G, et al. Residual inflammatory risk in patients with low LDL cholesterol levels undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2019;73(19):24019.

Article PubMed Google Scholar

Pradhan AD, Aday AW, Rose LM, Ridker PM. Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy. Circulation. 2018;138(2):1419.

Article CAS PubMed PubMed Central Google Scholar

Ridker PM. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J. 2016;37(22):17202.

Article PubMed Google Scholar

Li Y, Huang Z, Jin C, Xing A, Liu Y, Huangfu C, Lichtenstein AH, Tucker KL, Wu S, Gao X. Longitudinal change of Perceived Salt Intake and Stroke Risk in a Chinese Population. Stroke. 2018;49(6):13329.

Article PubMed PubMed Central Google Scholar

Zhou YF, Chen S, Wang G, Chen S, Zhang YB, Chen JX, Tu ZZ, Liu G, Wu S, Pan A. Effectiveness of a Workplace-Based, Multicomponent Hypertension Management Program in Real-World practice: a propensity-matched analysis. Hypertension. 2022;79(1):23040.

Article CAS PubMed Google Scholar

Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497505.

Article CAS PubMed Google Scholar

Wang X, Wu S, Yuan X, Chen S, Fu Q, Sun Y, Lan Y, Hu S, Wang Y, Lu Y, et al. Metabolic dysfunction-associated fatty liver disease and mortality among chinese adults: a prospective cohort study. J Clin Endocrinol Metab. 2022;107(2):e74555.

Article PubMed Google Scholar

Zhou YF, Wang Y, Wang G, Zhou Z, Chen S, Geng T, Zhang YB, Wang Y, Chen JX, Pan A, et al. Association between Statin Use and Progression of arterial stiffness among adults with high atherosclerotic risk. JAMA Netw Open. 2022;5(6):e2218323.

Article PubMed PubMed Central Google Scholar

Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of Statin Adherence with mortality in patients with atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2019;4(3):20613.

Article PubMed PubMed Central Google Scholar

Herttua K, Martikainen P, Batty GD, Kivimaki M. Poor adherence to statin and antihypertensive therapies as risk factors for fatal stroke. J Am Coll Cardiol. 2016;67(13):150715.

Article PubMed PubMed Central Google Scholar

Hageman SHJ, McKay AJ, Ueda P, Gunn LH, Jernberg T, Hagstrom E, Bhatt DL, Steg PG, Lall K, Magi R, et al. Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm. Eur Heart J. 2022;43(18):171527.

Article CAS PubMed PubMed Central Google Scholar

Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tershakovec AM, Blazing MA, Braunwald E. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015;132(13):122433.

Article CAS Google Scholar

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):117582.

Article CAS PubMed Google Scholar

Zhang X, Lv W, Xu J, Li J, Pan Y, Yan H, Li H, Li Z, Meng X, Wang Y. The contribution of inflammation to Stroke recurrence attenuates at low LDL-C levels. J Atheroscler Thromb. 2022;29(11):163445.

Article PubMed PubMed Central Google Scholar

Navarese EP, Robinson JG, Kowalewski M, Kolodziejczak M, Andreotti F, Bliden K, Tantry U, Kubica J, Raggi P, Gurbel PA. Association between Baseline LDL-C level and Total and Cardiovascular Mortality after LDL-C lowering: a systematic review and Meta-analysis. JAMA. 2018;319(15):156679.

Article CAS PubMed PubMed Central Google Scholar

Schubert J, Lindahl B, Melhus H, Renlund H, Leosdottir M, Yari A, Ueda P, James S, Reading SR, Dluzniewski PJ, et al. Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a swedish nationwide cohort study. Eur Heart J. 2021;42(3):24352.

Article CAS PubMed Google Scholar

Lauffenburger JC, Robinson JG, Oramasionwu C, Fang G. Racial/Ethnic and gender gaps in the use of and adherence to evidence-based preventive therapies among elderly Medicare Part D beneficiaries after acute myocardial infarction. Circulation. 2014;129(7):75463.

Article PubMed Google Scholar

Puri R, Nissen SE, Arsenault BJ, St John J, Riesmeyer JS, Ruotolo G, McErlean E, Menon V, Cho L, Wolski K, et al. Effect of C-Reactive protein on lipoprotein(a)-Associated Cardiovascular Risk in optimally treated patients with high-risk vascular disease: a prespecified secondary analysis of the ACCELERATE Trial. JAMA Cardiol. 2020;5(10):113643.

Article PubMed Google Scholar

Chang JJ, Katsanos AH, Khorchid Y, Dillard K, Kerro A, Burgess LG, Goyal N, Alexandrov AW, Alexandrov AV, Tsivgoulis G. Higher low-density lipoprotein cholesterol levels are associated with decreased mortality in patients with intracerebral hemorrhage. Atherosclerosis. 2018;269:1420.

Article CAS PubMed Google Scholar

Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol. 2013;168(6):512634.

Article PubMed Google Scholar

Stancel N, Chen CC, Ke LY, Chu CS, Lu J, Sawamura T, Chen CH. Interplay between CRP, atherogenic LDL, and LOX-1 and its potential role in the pathogenesis of atherosclerosis. Clin Chem. 2016;62(2):3207.

Article CAS PubMed Google Scholar

Ridker PM. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the treatment of atherothrombosis. Circ Res. 2019;124(3):43750.

Article CAS PubMed PubMed Central Google Scholar

Koskinas KC, Zaugg S, Yamaji K, Garcia-Garcia HM, Taniwaki M, Klingenberg R, Moschovitis A, Luscher TF, van Tits LJ, Matter CM, et al. Changes of coronary plaque composition correlate with C-reactive protein levels in patients with ST-elevation myocardial infarction following high-intensity statin therapy. Atherosclerosis. 2016;247:15460.

Article CAS PubMed Google Scholar

Andersson J, Johansson L, Ladenvall P, Wiklund PG, Stegmayr B, Jern C, Boman K. C-reactive protein is a determinant of first-ever stroke: prospective nested case-referent study. Cerebrovasc Dis. 2009;27(6):54451.

Article CAS PubMed Google Scholar

Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009;27(13):221724.

Article CAS PubMed Google Scholar

Schillaci G, Pirro M. C-reactive protein in hypertension: clinical significance and predictive value. Nutr Metab Cardiovasc Dis. 2006;16(7):5008.

Article CAS PubMed Google Scholar

Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):138797.

Article CAS PubMed Google Scholar

Bian F, Yang X, Zhou F, Wu PH, Xing S, Xu G, Li W, Chi J, Ouyang C, Zhang Y, et al. C-reactive protein promotes atherosclerosis by increasing LDL transcytosis across endothelial cells. Br J Pharmacol. 2014;171(10):267184.

Article CAS PubMed PubMed Central Google Scholar

Read the original post:
Effect of dual residual risk of cholesterol and inflammation on all ... - Cardiovascular Diabetology